WebNasdaq Biotechnology Index -3.45% -5.40% 8.26% -2.43% 10.01% 4.45% 9.91% -- As of March 23, 2024. Returns for periods of 1 year and above are annualized. Annual … WebJan 5, 2024 · Tremendous growth has taken place within the small-cap biotech space over the past two years. Let’s examine how recent additions to the Nasdaq Biotechnology …

XBI: SPDR® S&P® Biotech ETF - State Street Global Advisors

WebRecent Performance Biotechnology has been a relative underperformer in 2024, with the Nasdaq Biotechnology Index (NBI) down 1.3% on a YTD, price-return basis as of May 14 vs. a broader market gain of 11.3% as indicated by the S&P 500 Index (SPX). Looking at the S&P Biotechnology Select Industry Index (SPSIBI), the YTD loss is more material, WebApr 6, 2024 · XBI is one of a handful of biotech ETFs available, offering exposure to a corner of the market that can perform well during periods of consolidation and is capable of big jumps in the event of major drug approvals. XBI focuses on a narrow sector of the health care sector, and as such is probably too precise for most investors seeking to construct a … cyril bailly flavigny sur moselle

XBI: SPDR® S&P® Biotech ETF - State Street Global Advisors

WebNov 25, 2024 · “argenx SE (NASDAQ:ARGX) is a biotechnology company focused on autoimmune disorders. Shares gave back some gains in the quarter following strong stock performance relative to the broad market and biotechnology indexes. Sales of newly launched drug Vyvgart have tripled consensus expectations, and global approvals are … WebETFs Tracking Other Health & Biotech Equities. ETF Database staff has allocated each ETF in the ETF database, as well as each index, to a single ‘best-fit’ ETF Database Category. Other ETFs in the Health & Biotech Equities ETF Database Category are presented in the following table. * Assets in thousands of U.S. Dollars. WebSPDR® S&P® Biotech ETF XBI Fact Sheet Equity As of 12/31/2024 Key Features • ®The SPDR® S&P Biotech ETF seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P® Biotechnology Select IndustryTM Index (the “Index”) • Seeks to provide exposure to … cyril baldwin